217 related articles for article (PubMed ID: 34521550)
1. Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers.
Yoshikawa T
Vaccine; 2021 Oct; 39(41):6174-6181. PubMed ID: 34521550
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of Modified Vaccinia virus Ankara vaccines.
Gilbert SC
Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
Sutter G; Staib C
Curr Drug Targets Infect Disord; 2003 Sep; 3(3):263-71. PubMed ID: 14529359
[TBL] [Abstract][Full Text] [Related]
4. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.
Perdiguero B; Pérez P; Marcos-Villar L; Albericio G; Astorgano D; Álvarez E; Sin L; Gómez CE; García-Arriaza J; Esteban M
J Mol Biol; 2023 Aug; 435(15):168173. PubMed ID: 37301278
[TBL] [Abstract][Full Text] [Related]
5. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
Volz A; Sutter G
Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
[TBL] [Abstract][Full Text] [Related]
6. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
Volkmann A; Williamson AL; Weidenthaler H; Meyer TPH; Robertson JS; Excler JL; Condit RC; Evans E; Smith ER; Kim D; Chen RT;
Vaccine; 2021 May; 39(22):3067-3080. PubMed ID: 33077299
[TBL] [Abstract][Full Text] [Related]
7. Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus.
Medaglia ML; Moussatché N; Nitsche A; Dabrowski PW; Li Y; Damon IK; Lucas CG; Arruda LB; Damaso CR
J Virol; 2015 Dec; 89(23):11909-25. PubMed ID: 26378174
[TBL] [Abstract][Full Text] [Related]
8. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
[TBL] [Abstract][Full Text] [Related]
10. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.
Verardi PH; Titong A; Hagen CJ
Hum Vaccin Immunother; 2012 Jul; 8(7):961-70. PubMed ID: 22777090
[TBL] [Abstract][Full Text] [Related]
11. L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines.
Pacchioni SM; Bissa M; Zanotto C; Morghen Cde G; Illiano E; Radaelli A
J Transl Med; 2013 Apr; 11():95. PubMed ID: 23578094
[TBL] [Abstract][Full Text] [Related]
12. Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.
Lorenzo MM; Nogales A; Chiem K; Blasco R; Martínez-Sobrido L
Microbiol Spectr; 2022 Jun; 10(3):e0027222. PubMed ID: 35583360
[TBL] [Abstract][Full Text] [Related]
13. Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector.
Pavot V; Sebastian S; Turner AV; Matthews J; Gilbert SC
Methods Mol Biol; 2017; 1581():97-119. PubMed ID: 28374245
[TBL] [Abstract][Full Text] [Related]
14. A Multiplex PCR/LDR Assay for the Simultaneous Identification of Category A Infectious Pathogens: Agents of Viral Hemorrhagic Fever and Variola Virus.
Das S; Rundell MS; Mirza AH; Pingle MR; Shigyo K; Garrison AR; Paragas J; Smith SK; Olson VA; Larone DH; Spitzer ED; Barany F; Golightly LM
PLoS One; 2015; 10(9):e0138484. PubMed ID: 26381398
[TBL] [Abstract][Full Text] [Related]
15. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
16. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.
Grandpre LE; Duke-Cohan JS; Ewald BA; Devoy C; Barouch DH; Letvin NL; Reinherz EL; Baden LR; Dolin R; Seaman MS
Vaccine; 2009 Mar; 27(10):1549-56. PubMed ID: 19168105
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.
Kreijtz JH; Süzer Y; Bodewes R; Schwantes A; van Amerongen G; Verburgh RJ; de Mutsert G; van den Brand J; van Trierum SE; Kuiken T; Fouchier RA; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Gen Virol; 2010 Nov; 91(Pt 11):2745-52. PubMed ID: 20719991
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8.
Eto A; Saito T; Yokote H; Kurane I; Kanatani Y
Vaccine; 2015 Nov; 33(45):6106-11. PubMed ID: 26319072
[TBL] [Abstract][Full Text] [Related]
20. Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs.
Busquets N; Lorenzo G; López-Gil E; Rivas R; Solanes D; Galindo-Cardiel I; Abad FX; Rodríguez F; Bensaid A; Warimwe G; Gilbert SC; Domingo M; Brun A
Antiviral Res; 2014 Aug; 108():165-72. PubMed ID: 24933081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
